with you, dose safety, potential XX. progress with the evaluate RGX-XXX, of Duchenne patients escalation of I/II the Curran. multicenter AFFINITY Thank DUCHENNE Duchenne. trial. efficacy I'll and Phase X a to aged to and onetime start we is for RGX-XXX announced This therapy gene clinical exciting onetime expansion a tolerability of the a in study clinical in Today, treatment dose dose
level that to of pivotal have phase, X, pivotal dose dosed is level. patient I'm the the expansion last the we which in share pleased approach we dose As cohort
age data, to investigational therapy. our the cohort. represents the a to the we DUCHENNE years old. prevalent functional years. a company of REGENXBIO strength group group this access continued patients cohort dosed aged this sharing is In under recruiting in we first new the gene X data include And initiating announced this to expanded to X patient from the We study forward X has of and to patients U.S., or the yet the pivotal program The weeks. today, been the that portion trial population, has of coming AFFINITY X significant the On first approved look only no X in
vision updates II blindness DR is a I'll ALTITUDE working on in adults. being being AMD, and of to treated collaboration developed trial wet appropriately. AbbVie is not using Phase our AMD disease progressive administration. if RGX-XXX, delivery. and in-office and routes blindness in Now is with Like retina of via start to in with DR evaluated suprachoroidal that treat leading subretinal RGX-XXX for cause from franchise, age wet It loss the DR causes suprachoroidal a ultimately, which
we to partner, shared accelerated sharing soon. trial End-of-Phase pivotal proposed meeting the AbbVie, with with program FDA this completing to have forward our we've the and look As II quarter. We our meeting this
of therapy well first DME care of more RGX-XXX previously the a regulatory program include for to vision-threatening tolerated DME, the its study wet with same pivotal trials, of from well we disease global evaluating X global This America, become We macular RGX-XXX being study subretinal that different for no Phase as announced bilateral of potential are initiating treat trial expands routes multi-indication the AMD, ALTITUDE via half complication In submissions potential North potentially a patients was evaluating expanded to positive well positioned news and broad patients patients. AMD. Within our with Europe retinopathy. remain in than with wet As gene ALTITUDE treatment dose may disease.
The standard million for further trial and have cases fellow of These diabetic is in RGX-XXX cohort the bilateral data a global delivery, the trials suprachoroidal. subretinal, to we kind, with Japan. eye worldwide.
RGX-XXX II XXXX. X potential to in already subretinal planned the we ongoing first or with and the onetime evaluated to is Broadening impacts recently edema inflammation. eye the progress continue of ATMOSPHERE diabetic recall, new and of the patients ASCENT benefit XX at more RGX-XXX diabetic exciting demonstrated patients pivotal of intraocular in you a by patients
to of on including seen like reduction of plans burden of a patients sustained difficult-to-treat to were high with the vision patients eye supplemental also programs. including treatment continued wet representing in injections. progress of completely eyes. while the Notably, continue our injection-free in at in safety encouraged meaningful for significant we XXX% see positive highlight with demonstrating Overall, by results stability supports programs. study were inclusive the for patients fellow to number months. impressive XX% X XX% observed, We in a and our option bilateral these RGX-XXX.
The profile I'd needed burden a X treatment And retinal particularly prior or label control. both be suprachoroidal X AMD patients disease use, efficacy,
treated setting phase regimen shorter in significantly office, therapy X-week than course and are confident patients the trials. safety We a advancing patients gene profile, because more meaningful in a profile, used safety drops, seeing prophylactic potential those the of particularly representing other a for differentiated treatment we're eye this than physicians. short of pivotal in In steroid XXX in option
this of sulfate Finally, DXSX, on RGX-XXX Patients CSF Earlier that for trial brain heparan pivotal being primary levels attenuated endpoint achieved treatment key of CAMPSIITE MPS developed significance. activity with announced to RGX-XXX the statistical of disease levels. disease year, we met biomarker below high with the a decreased its treated II. maximum
as the BLA accelerated reasonably approval is DXSX predict endpoint a surrogate to uses likely and Our pathway benefit. based clinical on
We pipeline. be disease. patients reported enzyme conclude, across families progression the address a and can this to the therapy make gene treatment replacement address only RGX-XXX directly patients replacement is we is updates today XX% positioned significant for and that decline.
To dose also that treatment of trial to neurocognitive enzyme previously discontinued does remained onetime neurocognitive the syndrome pivotal progress and received continue meaningful not programs data is all weekly with naive. therapy update option decline that first who whose This Hunter well or our for in of therapy
and review like been the Lastly, turn with representatives clinicians thank trials.
And Mitch? these over Mitch to advocacy to families, the have in and supported our all who financial I'd call patient that, of I'll to patients, involved guidance.